Novartis has struck a front-loaded deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion, ...

Since Xaira’s eye-popping $1 billion fundraise in 2024, the company has said relatively little in public. | What has Xaira been doing since its $1 billion raise? Xaira COO Jeff Jonker joins "The Top ...

Intuitive Surgical is recalling one set of its stapler reloads used by its da Vinci robot after incomplete deliveries failed to properly close blood vessels during procedures.  | This comes in the ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | Renowned cardiologist Eric Topol, M.D., is setting sail with ...

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

Gilead has handed back a next-gen hepatitis B (HBV) antiviral to Assembly Biosciences, while the two companies continue to partner on other assets. It means Assembly is now back in sole control of ABI ...

Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint. | Genentech has ...

Diabetes hardware company embecta aims to look beyond insulin and reshape itself into a more varied drug delivery provider—and it’s kick-starting that effort with the acquisition of a glo | Embecta ...

As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration ...

Stoke Therapeutics is developing a drug designed to reduce seizures and restore some of their lost developmental function.

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Phage-focused BiomX is undergoing a “strategic and financial reset” in efforts to improve its position, mapping out a possible shift from therapeutics to the defense sector.   | Phage-focused BiomX is ...